Medication info
Nanubia Tablets 25 mg (Sitagliptin Hydrochloride Hydrate)

Nanubia Tablets 25 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›28.35mg / 1 tablet
Manufacturer / importer
HuTechs Pharmaceutical Co., Ltd.
Appearance
Pink, round, biconvex film-coated tablet
Packaging
28 tablets / box [(14 tablets / PTPX2)]
Approval status
Active

MFDS item code 202101255 · Approved 2021.02.10 · Insurance code 649105250

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
HuTechs Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty controlling blood sugar
View approved original text

This medication is used in conjunction with dietary control and exercise therapy to help manage blood sugar levels in patients with type 2 diabetes. It may be administered alone at the beginning of treatment. If blood sugar control is difficult with monotherapy, it may be used together with metformin. If sufficient blood sugar control is not achieved with other diabetes treatments such as sulfonylureas, metformin, thiazolidinedione, or insulin, this medication can be added as an adjunct therapy. It effectively improves blood sugar control tailored to various treatment situations.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication can cause rare but serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur after taking this medication, stop taking it immediately and consult a healthcare professional. This medication can cause pancreatitis, which is inflammation of the pancreas, so notify a healthcare professional immediately if symptoms such as abdominal pain, vomiting, or nausea occur. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication, nor should individuals with hypersensitivity to this medication or its ingredients. Patients with reduced kidney function should have their dosages adjusted, and regular kidney function tests are important. Hypoglycemia can occur while taking this medication, especially when used with insulin or sulfonylureas, so blood glucose levels should be monitored closely and dosages adjusted as necessary. This medication can cause serious side effects such as severe joint pain or blistering dermatitis, so consult a doctor immediately if any of these symptoms occur. Pregnant or breastfeeding women are advised not to take this medication, and safety and efficacy have not been established in children or adolescents under 18 years of age. Older patients may have reduced kidney function, so it is necessary to periodically check kidney function before and during treatment with this medication. In case of an overdose, general symptomatic treatment is performed, and renal dialysis may be required to remove the medication if necessary. This medication generally has less interaction with other hypoglycemic agents, but caution is needed when used with certain medications, so it is important to inform healthcare professionals of any other medications being taken.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • headache
  • diarrhea
  • abdominal pain
Show 30 more
  • nausea
  • constipation
  • vomiting
  • rash
  • urticaria
  • cutaneous vasculitis
  • severe and disabling arthralgia
  • blistering pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • acute renal failure
  • elevated liver enzymes
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, round, biconvex film-coated tablet

Package unit

28 tablets / box [(14 tablets / PTPX2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.